Baxter International Inc. (BAX)

Environment story

Baxter's Environmental score reflects moderate commitment to decarbonization but reveals significant greenwashing risks and disclosure gaps. The company has published 2030 Corporate Responsibility Commitments anchored on three pillars (Deliver Sustainable Healthcare, Protect our Planet, Champion our People), yet critical Scope 3 emissions data remain undisclosed, and there is no clearly articulated net-zero target year disclosed in the 10-K or proxy. The 10-K explicitly states 'We expect to announce a refreshed commitments and goals set after the issuance of our 2025 Corporate Responsibility Report,' indicating current goals lack permanence. Supply chain vulnerabilities (Hurricane Helene disruption at North Cove facility, elevated freight and material costs) and reliance on plastic resins (oil-price sensitive) create significant physical climate risk. The company acknowledges climate impacts on manufacturing (water scarcity, extreme weather) and identifies transition risks but does not quantify Scope 1, 2, or 3 emissions in the 10-K filing itself. Renewable electricity percentage is not disclosed. Deduction applied for undisclosed Scope 3 emissions (-15), absent or late net-zero target (-15), and greenwashing signal from deferring commitments announcement to future report (-10 discretionary deduction under controversy framework).

Social story

Baxter's Social score reflects moderate governance of human capital but elevated concerns regarding labor relations and pay equity transparency. The company employs approximately 37,500 people globally (15,100 in U.S., 22,400 outside U.S.) and emphasizes competitive pay, health/safety, recruitment, training, and development. However, critical gaps include: (1) CEO-to-worker pay ratio is not disclosed in the proxy statement, preventing independent verification against the 200:1 threshold; (2) unionization of select workforce with collective bargaining agreements expiring in January 2027 and January 2029 creates labor disruption risk, though no documented union-suppression activities or major strikes in the last 24 months are disclosed; (3) leadership diversity metrics (executive/board composition) are not explicitly stated as a percentage in the proxy or 10-K, though the proxy highlights board refreshment and mentions three new independent directors added over three years and one female executive (Soriano) promoted to Global President role in December 2025; (4) supply-chain human-rights audits and unmitigated hazards (e.g., conflict minerals) are not detailed. The company does disclose anonymous engagement surveys administered by third parties and evidence of management responsiveness (stock ownership guideline amendments in response to shareholder feedback). Deduction applied for undisclosed CEO-to-median-worker ratio (-15, unable to confirm compliance), and for unionization risk with expiring contracts (-10, mitigated by lack of recent strike activity).

Governance story

Baxter's Governance score reflects moderately strong board independence and oversight structures, but significant constraints from dual-class voting risk and active lobbying exposure. Board independence is estimated at ~89% (8 of 9 directors independent as of proxy filing; Andrew Hider, CEO, is non-independent; all other nominees are independent). Single-class share structure (no dual-class supermajority founder voting disclosed). Board has implemented majority voting standard for director elections, robust refreshment practices (three new independent directors added in past three years), and separated Chair and CEO roles in connection with Hider's August 2025 appointment. However, governance score penalized for: (1) lobbying expenditure directed at regulatory deregulation and tariff/trade policy (explicit Risk Factor disclosure on Section 232 investigation, tariff exclusion renewals, and 're-shoring' policies suggest active engagement with government on healthcare trade/tariffs; no dollar figure disclosed); (2) multiple regulatory and litigation matters disclosed, including FDA warning letters, product recalls (Novum IQ Large Volume Pump voluntary correction and ship-hold in 2025), and patent litigation. The 10-K does not disclose annual lobbying spend in dollars. No evidence of antitrust investigations or consumer-safety consent decrees active in 2025 disclosed; prior SEC matters and regulatory actions exist but not quantified as 'active.' Deduction applied for undisclosed lobbying spend (-10 discretionary, medium severity), regulatory/quality issues (-5 partial deduction recognizing quality-driven recall management).

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Baxter International Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Baxter International Inc. in the app for interactive charts and portfolio building.

More in Healthcare